There are 805 resources available
132MO - Anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC): Updated results from a phase I study
Presenter: Jian Zhang
Session: Mini Oral session: Gastrointestinal tumours
Resources:
Abstract
138MO - Baseline characteristics and molecular testing of patients with IDH1-mutated cholangiocarcinoma: Initial results from the phase IIIb ProvIDHe study
Presenter: Lorenza Rimassa
Session: Mini Oral session: Gastrointestinal tumours
Resources:
Abstract
73MO - Sotorasib (soto), panitumumab (pani), and FOLFIRI in first-line (1L) KRAS G12C–mutated metastatic colorectal cancer (mCRC): Regional analysis of safety and efficacy from CodeBreaK 101
Presenter: Toshiki Masuishi
Session: Mini Oral session: Gastrointestinal tumours
Resources:
Abstract
74MO - mFOLFOX6 + bevacizumab + PD-1 monoclonal antibody in locally advanced MSS CRC (BASKETⅡ): A prospective, single-arm, open-label, phase II study
Presenter: Jun Huang
Session: Mini Oral session: Gastrointestinal tumours
Resources:
Abstract
406MO - Unique molecular features of Epstein Barr virus-specific cytotoxic T lymphocyte (EBV-CTL) as biomarkers for advanced nasopharyngeal cancer (NPC) patients who received chemotherapy and EBV-CTL
Presenter: Timothy Shuen
Session: Mini Oral session: Head and neck cancers
Resources:
Abstract
37MO - HER2-low heterogeneity and its impact on benefit from trastuzumab deruxtecan in metastatic breast cancer
Presenter: Yutian Zou
Session: Mini Oral session: Breast cancer
Resources:
Abstract
407MO - Capecitabine combined with PD-1 antibody as maintenance therapy after first-line treatment of recurrent or metastatic nasopharyngeal carcinoma: A propensity score matching study
Presenter: Yifu Li
Session: Mini Oral session: Head and neck cancers
Resources:
Abstract
38MO - Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in patients (pts) with pre-treated inoperable/metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Results from TROPION-Breast01 China cohort
Presenter: Shusen Wang
Session: Mini Oral session: Breast cancer
Resources:
Abstract
LBA3 - First-line HLX07 vs. placebo combined with serplulimab and chemotherapy for nasopharyngeal cancer: A randomised, double-blind, multicentre phase II study
Presenter: Li Zhang
Session: Mini Oral session: Head and neck cancers
Resources:
Abstract
3MO - Efficacy of neoadjuvant pembrolizuamb in early triple-negative breast cancer according to germline BRCA-1/2 mutation
Presenter: Jee Hung Kim
Session: Mini Oral session: Breast cancer
Resources:
Abstract